The Potential Impact of Up-Front Drug Sensitivity Testing on India’s Epidemic of Multi-Drug Resistant Tuberculosis

• Kuldeep Singh Sachdeva,

  Affiliation Central TB Division, Government of India, New Delhi, India

  ⨯
• Neeraj Raizada ,

  * E-mail: drneerajraizada@gmail.com

  Affiliation Foundation for Innovative New Diagnostics, New Delhi, India

  ⨯
• Radhey Shyam Gupta,

  Affiliation Central TB Division, Government of India, New Delhi, India

  ⨯
• Sreenivas Achuthan Nair,

  Affiliation World Health Organization, India Country Office, New Delhi, India

  ⨯
• Claudia Denkinger,

  Affiliation Foundation for Innovative New Diagnostics, New Delhi, India

  ⨯
• Chinnambedu Nainarappan Paramasivan,

  Affiliation Foundation for Innovative New Diagnostics, New Delhi, India

  ⨯
• Shubhangi Kulsange,

  Affiliation Foundation for Innovative New Diagnostics, New Delhi, India

  ⨯
• Rahul Thakur,

  Affiliation Foundation for Innovative New Diagnostics, New Delhi, India

  ⨯
• Puneet Dewan,

  Affiliation Bill and Melinda Gates Foundation, New Delhi, India

  ⨯
• Catharina Boehme,

  Affiliation Foundation for Innovative New Diagnostics, New Delhi, India

  ⨯
• Nimalan Arinaminpathy

  Affiliation Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, United Kingdom

  ⨯